Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Hold" from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given a consensus recommendation of "Hold" by the seven brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $4.50.

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price target for the company in a research report on Thursday.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Algert Global LLC increased its position in Fulcrum Therapeutics by 6.0% during the first quarter. Algert Global LLC now owns 36,147 shares of the company's stock worth $104,000 after buying an additional 2,030 shares in the last quarter. American Century Companies Inc. raised its position in shares of Fulcrum Therapeutics by 2.6% in the first quarter. American Century Companies Inc. now owns 123,711 shares of the company's stock valued at $356,000 after buying an additional 3,100 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Fulcrum Therapeutics by 2.3% in the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock worth $667,000 after acquiring an additional 3,126 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics during the 4th quarter worth $38,000. Finally, Brooklyn Investment Group lifted its stake in shares of Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after purchasing an additional 8,254 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded down $0.24 on Wednesday, hitting $6.64. 78,837 shares of the company's stock were exchanged, compared to its average volume of 964,305. The firm has a market cap of $358.31 million, a price-to-earnings ratio of -21.61 and a beta of 2.29. The firm's 50-day moving average price is $3.69 and its two-hundred day moving average price is $3.80. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, research analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.